Literature DB >> 10945596

Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication.

M Mesnil1, H Yamasaki.   

Abstract

Antitumor suicide gene therapy is one of the emerging strategies against cancer. It consists of the introduction into cancer cells of a gene capable of converting a nontoxic prodrug into a cytotoxic drug. Because this therapeutic gene cannot be easily introduced into the whole cell population of a tumor, the successful eradication of tumors depends on a phenomenon called the "bystander effect," by which the introduced gene can affect even cells in which it is not itself present. From a therapeutic point of view, it may be crucial to enhance this phenomenon through various means to achieve tumor eradication. One such suicide gene, the thymidine kinase gene from the herpes simplex virus, in combination with the prodrug ganciclovir, has been extensively and successfully used in some animal models exhibiting a strong bystander effect. Among the mechanisms involved in this phenomenon, gap junctional intercellular communication (GJIC) is directly involved in the transfer of the toxic metabolites of ganciclovir, which pass directly from herpes simplex virus thymidine kinase-expressing cells to surrounding cells that do not express it. Because GJIC appears to be a mediator of the bystander effect both in vitro and in vivo, here we review possible molecular strategies for enhancing the extent of tumor cell death by increasing the intratumoral GJIC capacity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10945596

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  83 in total

1.  Cytokine regulation of gap junction connectivity: an open-and-shut case or changing partners at the Nexus?

Authors:  C F Brosnan; E Scemes; D C Spray
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

2.  Targeted cytoplasmic irradiation induces bystander responses.

Authors:  Chunlin Shao; Melvyn Folkard; Barry D Michael; Kevin M Prise
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-02       Impact factor: 11.205

Review 3.  Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.

Authors:  Kurt M Kroeger; A K M Ghulam Muhammad; Gregory J Baker; Hikmat Assi; Mia K Wibowo; Weidong Xiong; Kader Yagiz; Marianela Candolfi; Pedro R Lowenstein; Maria G Castro
Journal:  Discov Med       Date:  2010-10       Impact factor: 2.970

Review 4.  Role of gap junctions in embryonic and somatic stem cells.

Authors:  Raymond C B Wong; Martin F Pera; Alice Pébay
Journal:  Stem Cell Rev       Date:  2008-12       Impact factor: 5.739

Review 5.  Besides Purkinje cells and granule neurons: an appraisal of the cell biology of the interneurons of the cerebellar cortex.

Authors:  Karl Schilling; John Oberdick; Ferdinando Rossi; Stephan L Baader
Journal:  Histochem Cell Biol       Date:  2008-08-02       Impact factor: 4.304

6.  Suicide gene approach using a dual-expression lentiviral vector to enhance the safety of ex vivo gene therapy for bone repair.

Authors:  F Alaee; O Sugiyama; M S Virk; H Tang; H Drissi; A C Lichtler; J R Lieberman
Journal:  Gene Ther       Date:  2013-11-28       Impact factor: 5.250

7.  Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma.

Authors:  Liliana M E Finocchiaro; Chiara Fondello; María L Gil-Cardeza; Úrsula A Rossi; Marcela S Villaverde; María D Riveros; Gerardo C Glikin
Journal:  Hum Gene Ther       Date:  2015-05-26       Impact factor: 5.695

8.  Connexins and apoptotic transformation.

Authors:  Audrone Kalvelyte; Ausra Imbrasaite; Angele Bukauskiene; Vytas K Verselis; Feliksas F Bukauskas
Journal:  Biochem Pharmacol       Date:  2003-10-15       Impact factor: 5.858

Review 9.  Transcriptionally targeted gene therapy to detect and treat cancer.

Authors:  Lily Wu; Mai Johnson; Makoto Sato
Journal:  Trends Mol Med       Date:  2003-10       Impact factor: 11.951

Review 10.  Gene therapy of benign gynecological diseases.

Authors:  Memy H Hassan; Essam E Othman; Daniela Hornung; Ayman Al-Hendy
Journal:  Adv Drug Deliv Rev       Date:  2009-05-13       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.